This HTML5 document contains 77 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00520/identifier/chebi/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/AHFS/
n10http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n6http://linked.opendata.cz/resource/mesh/concept/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00520/identifier/wikipedia/
n21http://linked.opendata.cz/resource/drugbank/dosage/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00520/identifier/pharmgkb/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00520/identifier/pubchem-compound/
n13http://bio2rdf.org/drugbank:
n24http://linked.opendata.cz/resource/drugbank/drug/DB00520/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n25http://linked.opendata.cz/resource/drugbank/drug/DB00520/identifier/kegg-drug/
n15http://www.rxlist.com/cgi/generic/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00520/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/patent/
n30http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n26http://linked.opendata.cz/resource/drugbank/drug/DB00520/identifier/national-drug-code-directory/
n3http://linked.opendata.cz/ontology/drugbank/
n20http://www.drugs.com/cdi/
n7http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n29http://linked.opendata.cz/resource/drugbank/drug/DB00520/identifier/chemspider/
n16http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00520
rdf:type
n3:Drug
n3:description
Caspofungin (brand name Cancidas worldwide) is an antifungal drug, the first of a new class termed the echinocandins from Merck & Co., Inc. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall. Caspofungin is administered intravenously.
n3:dosage
n21:271B64BA-363D-11E5-9242-09173F13E4C5 n21:271B64BB-363D-11E5-9242-09173F13E4C5 n21:271B64B8-363D-11E5-9242-09173F13E4C5 n21:271B64B9-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Letscher-Bru, Valérie, and Raoul Herbrecht. 2003. Caspofungin: the first representative of a new antifungal class. Journal of Antimicrobial Chemotherapy 51, no. 3 (March 1): 513 -521. "doi:10.1093/jac/dkg117":http://dx.doi.org/10.1093/jac/dkg117. # Sucher AJ, Chahine EB, Balcer HE: Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009 Oct;43(10):1647-57. Epub 2009 Sep 1. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19724014 # Morrison VA: Caspofungin: an overview. Expert Rev Anti Infect Ther. 2005 Oct;3(5):697-705. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16207161 # McCormack PL, Perry CM: Caspofungin: a review of its use in the treatment of fungal infections. Drugs. 2005;65(14):2049-68. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16162025 # Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm. 2006 Sep 15;63(18):1693-703. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16960253 # Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, Part 2. Am J Health Syst Pharm. 2006 Oct 1;63(19):1813-20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16990627
n3:group
approved
n3:halfLife
9-11 hours
n3:indication
For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.
n3:manufacturer
n10:271B64B5-363D-11E5-9242-09173F13E4C5
owl:sameAs
n13:DB00520 n30:DB00520
dcterms:title
Caspofungin
adms:identifier
n18:Caspofungin n19:PA164743013 n23:2826718 n24:46508288 n25:D07626 n26:0006-3822-10 n27:DB00520 n28:474180 n29:411774
n3:mechanismOfAction
Caspofungin inhibits the synthesis of beta-(1,3)-D-glucan, an essential component of the cell wall of <i>Aspergillus</i> species and <i>Candida</i> species. beta-(1,3)-D-glucan is not present in mammalian cells. The primary target is beta-(1,3)-glucan synthase.
n3:packager
n10:271B64B2-363D-11E5-9242-09173F13E4C5 n10:271B64B3-363D-11E5-9242-09173F13E4C5 n10:271B64B4-363D-11E5-9242-09173F13E4C5
n3:patent
n4:5378804 n4:2251928 n4:2118757 n4:5952300
n3:routeOfElimination
After single intravenous administration of [3H] caspofungin acetate, excretion of caspofungin and its metabolites in humans was 35% of dose in feces and 41% of dose in urine.
n3:synonym
1-[(4R,5S)-5-[(2-Aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin b0 (4R,5S)-5-((2-Aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(P-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide
n3:toxicity
Side effects include rash, swelling, and nausea (rare)
n8:hasAHFSCode
n9:08-14-16
n3:proteinBinding
97%
n3:salt
n3:synthesisReference
Johannes Ludescher, Ingolf Macher, Ole Storm, Stephan Bertel, "Process and Intermediates for the Synthesis of Caspofungin." U.S. Patent US20080319162, issued December 25, 2008.
n5:hasConcept
n6:M0414530
foaf:page
n15:caspofungin.htm n20:caspofungin.html
n3:IUPAC-Name
n7:271B64C0-363D-11E5-9242-09173F13E4C5
n3:InChI
n7:271B64C6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n7:271B64C5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B64C2-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n7:271B64C3-363D-11E5-9242-09173F13E4C5
n3:SMILES
n7:271B64C4-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n7:271B64BE-363D-11E5-9242-09173F13E4C5
n3:logP
n7:271B64D6-363D-11E5-9242-09173F13E4C5 n7:271B64BC-363D-11E5-9242-09173F13E4C5 n7:271B64BF-363D-11E5-9242-09173F13E4C5
n3:logS
n7:271B64BD-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n16:J02AX04
n3:H-Bond-Acceptor-Count
n7:271B64CC-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n7:271B64CD-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n7:271B64C7-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n7:271B64C8-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n7:271B64CA-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n7:271B64C9-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n7:271B64CB-363D-11E5-9242-09173F13E4C5
n3:absorption
92% tissue distribution within 36-48 hours after intravenous infusion
n3:affectedOrganism
Aspergillis, Candida and other fungi
n3:casRegistryNumber
162808-62-0
n3:category
n3:clearance
* 12 mL/min [After single IV administration]
n3:containedIn
n11:271B64B6-363D-11E5-9242-09173F13E4C5 n11:271B64B7-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n7:271B64D2-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n7:271B64D4-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n7:271B64D5-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n7:271B64D1-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n7:271B64D0-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n7:271B64D3-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n7:271B64C1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n7:271B64CE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n7:271B64CF-363D-11E5-9242-09173F13E4C5